Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

SELL
$11.12 - $22.2 $3,102 - $6,193
-279 Reduced 10.7%
2,328 $26,000
Q1 2023

May 12, 2023

SELL
$18.7 - $23.07 $5,535 - $6,828
-296 Reduced 10.2%
2,607 $52,000
Q4 2022

Feb 10, 2023

SELL
$18.12 - $27.32 $1,793 - $2,704
-99 Reduced 3.3%
2,903 $65,000
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $5,416 - $8,147
319 Added 11.89%
3,002 $56,000
Q2 2022

Aug 12, 2022

SELL
$13.15 - $20.45 $933 - $1,451
-71 Reduced 2.58%
2,683 $50,000
Q1 2022

May 13, 2022

SELL
$14.54 - $21.5 $101 - $150
-7 Reduced 0.25%
2,754 $50,000
Q4 2021

Feb 11, 2022

SELL
$20.24 - $36.01 $2,489 - $4,429
-123 Reduced 4.26%
2,761 $57,000
Q3 2021

Nov 12, 2021

BUY
$26.01 - $38.22 $75,012 - $110,226
2,884 New
2,884 $92,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.